Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cordis starts trial of new AAA stent

This article was originally published in Clinica

Executive Summary

A new stent called Incraft is being developed by Cordis as a treatment for abdominal aortic aneurysm (AAA). The Johnson & Johnson subsidiary has started an open-label, non-randomised trial called INNOVATION, which will enrol 25 AAA patients. The stent can be customised to the individual patient during the implantation procedure, and has an "ultra-low-profile delivery system". Incraft's delivery system profile is 13 French, whereas most endovascular aneurysm repair (EVAR) devices have a profile ranging from 18 to 24 French. This should broaden the patient population who can be treated with stents; many AAA patients, especially women, cannot undergo EVAR because current stents are too large to be placed in small or diseased access vessels. An estimated 27 million people worldwide have AAAs. Left untreated, all aneurysms will eventually rupture, and ruptured aneurysms are fatal in more than 80% of cases.

You may also be interested in...

Five minutes with… Noam Emanuel of PolyPid

Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.

Mesoblast's blood cancers stem cell therapy moves closer to market

Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.

Mesoblast stem cell therapy advances into Phase II for spinal degeneration

Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts